US breast cancer drug decision 'marks start of death panels'

US breast cancer drug decision 'marks start of death panels' - Telegraph: The FDA advisory panel has now voted 12-1 to drop the endorsement for breast cancer treatment. The panel unusually cited 'effectiveness' grounds for the decision. But it has been claimed that 'cost effectiveness' was the real reason ahead of reforms in which the government will extend health insurance to the poorest. If the approval of the drug is revoked then US insurers would be likely to stop paying for Avastin.